Afyx Therapeutics

Afyx Therapeutics is a biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases. For this purpose, Afyx Therapeutics has developed the Rivelin® patch, designed to deliver a pharmaceutical drug uni-directional to a mucosal surface – using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.

Afyx Therapeutics’ lead product candidate incorporates clobetasol proprionate to the Rivelin® patch targeting the currently unmet need of treating Oral Lichen Planus, a chronic condition that affect 1-2% of the population. This product candidate is currently in Phase 1b, with commencement of Phase 2b planned for 4Q 2017

Contact name:

Lars Siim Madsen


Lergravsvej 57, 2. tv., 2300 Copenhagen S, Denmark



If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 5150 0560

Copyright 2017 Danskbiotek. All rights reserved.